Defining Objective BASDAI Cut-Offs for Disease Activity States and Improvement Scores in Axial Spondyloarthritis: A Multicentric Collaboration.

IF 2.4 4区 医学 Q2 RHEUMATOLOGY
Rudra Prosad Goswami, Moumita Chatterjee, Shyamashis Das
{"title":"Defining Objective BASDAI Cut-Offs for Disease Activity States and Improvement Scores in Axial Spondyloarthritis: A Multicentric Collaboration.","authors":"Rudra Prosad Goswami, Moumita Chatterjee, Shyamashis Das","doi":"10.1111/1756-185X.15418","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To estimate objective cut-off values for Bath ankylosing Spondylitis Disease Activity Index (BASDAI) corresponding to Ankylosing Spondylitis Disease Activity Score with CRP (ASDAS) cut-off values (1.3, 2.1, and 3.5), and for interval changes (ΔBASDAI) corresponding to ΔASDAS (1.1 and 2).</p><p><strong>Methods: </strong>In this multicentric study, adult patients with active axial spondyloarthritis (axSpA) treated with either tofacitinib 5 mg twice daily or adalimumab 40 mg subcutaneously fortnightly were recruited. Available paired data on BASDAI and ASDAS and paired interval change of these parameters (taken at least 3-months apart) were analyzed. Cut-off values for BASDAI were determined from a multinomial logistic regression and that for ΔBASDAI were determined with ordinal logistic regression with predicted probabilities. Diagnostics were assessed with correct classification rate (CRR), polychoric correlations (PCC), Goodman and Kruskal Gamma (GKG), and Matthew's correlation coefficient (MCC).</p><p><strong>Results: </strong>Total 962 observations of paired data and 670 interval change data were available from 266 patient (mean age 35 years, mean disease duration 7 years, mean BASDAI 2.7, and mean ASDAS 2.1). Following ASDAS classes were observed: inactive disease 131 (13.6%), moderate disease activity 322 (33.5%), high disease activity 420 (43.65%), and very high disease activity 89 (9.25%). The three cut-offs generated for BASDAI were 0.8, 2.5, and 6 for BASDAI and those for ΔBASDAI were 2 and 4. The CRR for BASDAI cut-offs was 65.59 and that for ΔBASDAI was 54.9. For the BASDAI cut-offs, both PCC and GKG showed high values (> 0.85) and the MCC was 0.471.</p><p><strong>Conclusion: </strong>In patients with axSpA, without any clinical or serological confounders, BASDAI values 0.8, 2.5, and 6 corresponded to ASDAS-CRP values 1.3, 2.1, and 3.5, respectively, and ΔBASDAI values of 2 and 4 correspond to ΔASDAS cut-offs of 1.1 and 2.</p>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Rheumatic Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/1756-185X.15418","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To estimate objective cut-off values for Bath ankylosing Spondylitis Disease Activity Index (BASDAI) corresponding to Ankylosing Spondylitis Disease Activity Score with CRP (ASDAS) cut-off values (1.3, 2.1, and 3.5), and for interval changes (ΔBASDAI) corresponding to ΔASDAS (1.1 and 2).

Methods: In this multicentric study, adult patients with active axial spondyloarthritis (axSpA) treated with either tofacitinib 5 mg twice daily or adalimumab 40 mg subcutaneously fortnightly were recruited. Available paired data on BASDAI and ASDAS and paired interval change of these parameters (taken at least 3-months apart) were analyzed. Cut-off values for BASDAI were determined from a multinomial logistic regression and that for ΔBASDAI were determined with ordinal logistic regression with predicted probabilities. Diagnostics were assessed with correct classification rate (CRR), polychoric correlations (PCC), Goodman and Kruskal Gamma (GKG), and Matthew's correlation coefficient (MCC).

Results: Total 962 observations of paired data and 670 interval change data were available from 266 patient (mean age 35 years, mean disease duration 7 years, mean BASDAI 2.7, and mean ASDAS 2.1). Following ASDAS classes were observed: inactive disease 131 (13.6%), moderate disease activity 322 (33.5%), high disease activity 420 (43.65%), and very high disease activity 89 (9.25%). The three cut-offs generated for BASDAI were 0.8, 2.5, and 6 for BASDAI and those for ΔBASDAI were 2 and 4. The CRR for BASDAI cut-offs was 65.59 and that for ΔBASDAI was 54.9. For the BASDAI cut-offs, both PCC and GKG showed high values (> 0.85) and the MCC was 0.471.

Conclusion: In patients with axSpA, without any clinical or serological confounders, BASDAI values 0.8, 2.5, and 6 corresponded to ASDAS-CRP values 1.3, 2.1, and 3.5, respectively, and ΔBASDAI values of 2 and 4 correspond to ΔASDAS cut-offs of 1.1 and 2.

定义轴性脊柱关节炎疾病活动状态和改善评分的客观 BASDAI 临界值:多中心协作。
目的估算巴斯强直性脊柱炎疾病活动指数(BASDAI)与强直性脊柱炎疾病活动评分(ASDAS)临界值(1.3、2.1和3.5)相对应的客观临界值,以及与ΔASDAS(1.1和2)相对应的间期变化(ΔBASDAI):在这项多中心研究中,招募了接受托法替尼(tofacitinib)5 毫克、每天两次或阿达木单抗(adalimumab)40 毫克、每两周一次皮下注射治疗的活动性轴性脊柱关节炎(axSpA)成年患者。对 BASDAI 和 ASDAS 的现有配对数据以及这些参数的配对间隔变化(至少间隔 3 个月)进行了分析。BASDAI 的临界值通过多叉逻辑回归确定,ΔBASDAI 的临界值通过预测概率的序数逻辑回归确定。诊断结果通过正确分类率(CRR)、多变量相关系数(PCC)、Goodman 和 Kruskal Gamma(GKG)以及马修相关系数(MCC)进行评估:从 266 名患者(平均年龄 35 岁,平均病程 7 年,平均 BASDAI 2.7,平均 ASDAS 2.1)共获得 962 个配对数据观测值和 670 个区间变化数据。ASDAS 分级如下:非活动性疾病 131 例(13.6%)、中度疾病活动 322 例(33.5%)、高度疾病活动 420 例(43.65%)和极高度疾病活动 89 例(9.25%)。BASDAI 的三个临界值分别为 0.8、2.5 和 6,ΔBASDAI 的临界值分别为 2 和 4。BASDAI 临界值的 CRR 为 65.59,ΔBASDAI 临界值的 CRR 为 54.9。就 BASDAI 临界值而言,PCC 和 GKG 均显示高值(> 0.85),MCC 为 0.471:结论:在没有任何临床或血清学混杂因素的axSpA患者中,BASDAI值0.8、2.5和6分别对应于ASDAS-CRP值1.3、2.1和3.5,ΔBASDAI值2和4对应于ΔASDAS临界值1.1和2。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.70
自引率
4.00%
发文量
362
审稿时长
1 months
期刊介绍: The International Journal of Rheumatic Diseases (formerly APLAR Journal of Rheumatology) is the official journal of the Asia Pacific League of Associations for Rheumatology. The Journal accepts original articles on clinical or experimental research pertinent to the rheumatic diseases, work on connective tissue diseases and other immune and allergic disorders. The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. Except where otherwise stated, manuscripts are peer reviewed by two anonymous reviewers and the Editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信